A Phase 3 interventional study of AK-D101 and Placebo in Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder and ADHD, sponsored by Alvogen Korea. Not yet recruiting at 1 site in South Korea. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Alvogen Korea (part of Lotus Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Attention Deficit Disorder with Hyperactivity with a site in Korea, Republic of — 2 open to participants now, 2 under way, 1 of them phase 3. Attention Deficit Disorder with Hyperactivity · Korea, Republic of.
Among the 22 studies in Attention Deficit Disorder with Hyperactivity with a site in Korea, Republic of, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2026, is one of 6 in phase 3, and was the 22nd registered.
1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →2 of the 22 studies in Attention Deficit Disorder with Hyperactivity with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Neudive Inc. · Sites in Korea, Republic of
Ages 5–12
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 156 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 147 across the 18 interventional studies, 215 across the 4 observational. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alvogen Korea, one of the names counted as Lotus Pharmaceutical Co., Ltd.. Under that name alone:
Alvogen Korea is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Lotus Pharmaceutical Co., Ltd. has 1 study filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
1 of the studies in Attention Deficit Disorder with Hyperactivity with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07678827Phase 3Alvogen KoreaA Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Attention Deficit Disorder with Hyperactivity with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter bridging clinical trial designed to evaluate the efficacy and safety of viloxazine extended-release capsules (AK-D101) compared with placebo in Korean children and adolescents aged 6 to 17 years with attention-deficit/hyperactivity disorder (ADHD). Eligible participants will be randomized in a 1:1 ratio to receive AK-D101 or placebo once daily for 8 weeks. Randomization will be stratified by study site and age group (children aged 6 to 11 years and adolescents aged 12 to 17 years). The primary efficacy endpoint is the change from baseline to Week 8, End of Treatment, in the Korean ADHD Rating Scale, 5th Edition (K-ARS-5) Total Score.
This study is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 bridging clinical trial in Korean children and adolescents aged 6 to 17 years with ADHD. At Screening, written informed consent will be obtained from the participant's parent or legal representative, and assent will be obtained from the participant, as applicable, before any study-specific procedures are performed. Eligibility will be assessed at Screening and confirmed at Baseline.
Eligible participants will be stratified by study site and age group, defined as children aged 6 to 11 years and adolescents aged 12 to 17 years, and randomized in a 1:1 ratio to the AK-D101 group or placebo group through an Interactive Web Response System (IWRS). The study is double-blind; participants, investigators, site personnel, sponsor personnel, CRO personnel, and other personnel involved in study conduct or interpretation will remain blinded to treatment assignment.
Participants will receive the investigational product once daily in the morning for a total of 8 weeks. Treatment will start at 100 mg once daily. During the titration period of up to 3 weeks, the dose may be increased by 100 mg weekly at the investigator's discretion based on tolerability and response, up to a maximum dose of 400 mg once daily. At the end of titration, the maintenance dose will be determined as 200 mg, 300 mg, or 400 mg and will be continued for at least 5 weeks. To maintain blinding, placebo-treated participants will undergo mock titration using the same procedures.
Participants will visit the study site weekly from Visit 3 to Visit 6 for efficacy and safety assessments. Visits 7 and 9 will be conducted as phone-call visits to assess investigational product administration, concomitant medications or therapies, and adverse events. Visits 8, 10, and 11 will be on-site visits for efficacy and/or safety assessments. Visit 10 at Week 8/Day 56 is the End of Treatment visit. Visit 11 at Week 9/Day 63 is the End of Study visit for final safety follow-up. Participants who discontinue investigational product before completing the planned 56-day treatment period or withdraw early will undergo an Early Termination visit, with procedures corresponding to the End of Treatment visit, and will be followed until End of Study whenever feasible.
Pharmacokinetic assessments will be conducted in participants who consent to PK blood sampling. PK blood sampling will be performed at two blood sampling visits, Visit 3 and one of Visit 6, Visit 8, or Visit 10, according to the protocol-defined schedule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who meet the following body weight criteria at Visit 1 (Screening):
Subjects considered suitable for participation in the clinical trial by the investigator based on clinical laboratory tests, vital signs, and assessments, meeting all of the following criteria:
Exclusion Criteria:
Subjects who are currently taking viloxazine, who previously took viloxazine for the treatment of ADHD but discontinued it due to adverse reactions or lack of efficacy, or who have a history of allergic reaction, *, or intolerance to viloxazine extended-release capsules or any of their .
*Hypersensitivity-related excipients: lactose, sucrose, Yellow No. 5 (Sunset Yellow FCF), and Yellow No. 203 (Quinoline Yellow WS).
Subjects with a history of diagnosis of significant central nervous system (CNS) disease or neuromuscular disease, including:
Subjects who have taken any of the following medications within the specified period prior to the first dose of investigational medicinal product at Visit 2 (Baseline):
Females of childbearing potential, defined as those with confirmed menarche, who do not agree to use adequate during the study period and for 4 weeks after the last dose of the investigational medicinal product.
(*) Adequate contraception includes sexual abstinence, hormonal contraceptives without known drug interactions, intrauterine hormone-releasing systems, such as a levonorgestrel intrauterine system (IUS), intrauterine devices (IUDs), and surgical sterilization, including bilateral tubal ligation, salpingectomy, and vasectomy. However, periodic abstinence methods, such as calendar, symptothermal, or post-ovulation methods, use of spermicides alone, lactational amenorrhea method, double barrier methods, simultaneous use of female and male condoms, and withdrawal are not considered acceptable contraception.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the AK-D101 arm will receive viloxazine extended-release capsules once daily for 8 weeks. Treatment will start at 100 mg once daily. During the titration period of up to 3 weeks, the dose may be increased by 100 mg weekly at the investigator's discretion based on tolerability and response, up to a maximum of 400 mg once daily. At the end of the titration period, the maintenance dose will be determined as 200 mg, 300 mg, or 400 mg once daily and continued for at least 5 weeks.
Drug: AK-D101
Participants randomized to the placebo arm will receive matching placebo capsules once daily for 8 weeks. To maintain the double-blind design, placebo-treated participants will undergo mock titration according to the same procedures used in the AK-D101 group.
Drug: Placebo
Viloxazine extended-release capsules administered orally once daily in the morning for 8 weeks. The starting dose is 100 mg once daily. The dose may be increased by 100 mg weekly during titration, up to 400 mg once daily, based on investigator assessment of tolerability and response. The maintenance dose will be 200 mg, 300 mg, or 400 mg once daily.
Matching placebo capsules administered orally once daily in the morning for 8 weeks. Mock titration will be performed to maintain blinding.
Change From Baseline to Week 8 in K-ARS-5 (Korean ADHD Rating Scale, 5th Edition) Total Score
The Korean ADHD Rating Scale, 5th Edition (K-ARS-5) Total Score is used to assess ADHD symptoms. The total score ranges from 0 to 54, with higher scores indicating more severe ADHD symptoms. A negative change from baseline indicates improvement.
Time frame: Baseline to Week 8, End of Treatment
Change From Baseline in the Korean ADHD Rating Scale, 5th Edition Total Score at Each Scheduled Visit
The Korean ADHD Rating Scale, 5th Edition (K-ARS-5) Total Score is used to assess ADHD symptoms. The total score ranges from 0 to 54, with higher scores indicating more severe ADHD symptoms. A negative change from baseline indicates improvement.
Time frame: Baseline; Weeks 1, 2, 3, 4, 6, and 8
Clinical Global Impression-Improvement (CGI-I) Score by Visit
The Clinical Global Impression-Improvement (CGI-I) scale is used to assess overall clinical improvement compared with baseline. The CGI-I score ranges from 1 to 7, where 1 indicates "very much improved" and 7 indicates "very much worse." Lower scores indicate greater improvement.
Time frame: Weeks 1, 2, 3, 4, 6, and 8
Korean ADHD Rating Scale, 5th Edition(K-ARS-5) 50% Responder Rate by Visit
The Korean ADHD Rating Scale, 5th Edition (K-ARS-5) Total Score ranges from 0 to 54, with higher scores indicating more severe ADHD symptoms. A K-ARS-5 50% responder is defined as a participant with at least a 50% reduction from baseline in the K-ARS-5 Total Score.
Time frame: Weeks 1, 2, 3, 4, 6, and 8
CGI-I(Clinical Global Impression-Improvement) Responder Rate at Each Scheduled Visit
The Clinical Global Impression-Improvement (CGI-I) scale ranges from 1 to 7, where 1 indicates "very much improved" and 7 indicates "very much worse." Lower scores indicate greater improvement. A CGI-I responder is defined as a participant with a CGI-I score of 1 or 2.
Time frame: Weeks 1, 2, 3, 4, 6, and 8
Plan to share: No — Individual participant data will not be publicly shared because the study is sponsored for regulatory bridging purposes and the data may contain confidential, proprietary, and participant-level clinical information.
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Sep 2027, 14 months later.
Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's planned 14 months is above that.
Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity →